Staten Island Advance—
For nine years, 11-year-old Ethan Goldner has controlled his type 1 diabetes with Novolog, a fast-acting, manufactured form of human insulin.
That is, until Jan. 9, when his Prince’s Bay family’s insurance carrier said there must be a cheaper way.
The insurance carrier’s decision and the excruciating 12-day appeal process that followed as Ethan’s body rejected the cheaper drug filled their lives with fear and uncertainty as they watched their son’s health deteriorate.
Read more here.